Gastric acid inhibitory and gastric protective effects of Cannabis and cannabinoids  by Abdel-Salam, Omar
HOSTED BY Contents lists available at ScienceDirect
Asian Paciﬁc Journal of Tropical Medicine 2016; 9(5): 413–419 413Asian Paciﬁc Journal of Tropical Medicine
journal homepage: http://ees.elsevier.com/apjtmOriginal research http://dx.doi.org/10.1016/j.apjtm.2016.04.021*Corresponding author: Omar Abdel-Salam, Department of Toxicology and
Narcotics, Medical Division, National Research Centre, Tahrir Street, Dokki, Cairo,
Egypt.
E-mail: omasalam@hotmail.com
Peer review under responsibility of Hainan Medical College.
Foundation project: It was supported by the National Research Centre (No.
10001004).
1995-7645/Copyright © 2016 Hainan Medical College. Production and hosting by Elsevier B.V. This is an open access article under th
creativecommons.org/licenses/by-nc-nd/4.0/).Gastric acid inhibitory and gastric protective effects of Cannabis and cannabinoidsOmar Abdel-Salam*Department of Toxicology and Narcotics, Medical Division, National Research Centre, Tahrir Street, Dokki, Cairo, EgyptARTICLE INFO
Article history:
Received 15 Jan 2016
Received in revised form16 Feb 2016
Accepted 10 Mar 2016





Cannabis sativa has long been known for its psychotropic effect. Only recently with the
discovery of the cannabinoid receptors, their endogenous legends and the enzymes
responsible for their synthesis and degradation, the role of this ‘endocannabinoid system’
in different pathophysiologic processes is beginning to be delineated. There is evidence
that CB1 receptor stimulation with synthetic cannabinoids or Cannabis sativa extracts
rich in D9-tetrahydrocannabinol inhibit gastric acid secretion in humans and experimental
animals. This is specially seen when gastric acid secretion is stimulated by pentagastrin,
carbachol or 2-deoxy-D-glucose. Cannabis and/or cannabinoids protect the gastric mu-
cosa against noxious challenge with non-steroidal anti-inﬂammatory drugs, ethanol as
well as against stress-induced mucosal damage. Cannabis/cannabinoids might protect the
gastric mucosa by virtue of its antisecretory, antioxidant, anti-inﬂammatory, and vaso-
dilator properties.1. Introduction
Cannabis is the most commonly abused illicit substance
worldwide. The two commonly used Cannabis preparations are
herbal Cannabis or marijuana (prepared from the dried ﬂowering
tops and leaves) and hashish (consists of dried Cannabis resin
and compressed ﬂowers). Both are derived from the female plant
of Cannabis sativa Linn (family Cannabidaceae) [1]. Research
into Cannabis led to discovery of its active constituents or
cannabinoids, a terpeno-phenol compounds; more than 70 of
which have been isolated. The most studied cannabinoids are
D9-tetrahydrocannabinol (THC), cannabinol, cannabidiol, can-
nabigerol, cannabichromene, D9-tetrahydrocannabivarin, can-
nabidivarin and others [2,3]. D9-THC is the primary constituent
that is responsible for the psychotropic properties of
recreational Cannabis [4].
Cannabinoids mediate their biological effects through inter-
action with cannabinoid receptors, which belong to the super-
family of G protein-coupled receptors. There are at least two
cannabinoid receptor subtypes: the CB1 receptor, essentially
located in the central nervous system, but also in peripheraltissues, and the CB2 receptor, found only at the periphery
especially on immune cells [5]. Most of Cannabis effects in the
central nervous system are mediated by CB1 receptors. These are
expressed at brain areas that control movements, memory,
cognition and emotion and in the spinal cord [6,7] where they
mediate retrograde inhibition of neuronal activity [8].
Cannabinoid receptors can also be activated by a number of
endogenous ligands, the endocannabinoids. The main endo-
cannabinoids, arachidonoyl ethanolamide (anandamide) and 2-
arachidonoyl glycerol (2-AG) are selective agonists at the CB1
and CB2 receptors, respectively. Both are derivatives of arach-
idonic acid, that are produced and released ‘on demand’ by
cleavage of membrane lipid precursors and are hydrolysed by
the fatty acid amide hydrolase anandamide or monoglyceride
lipase, respectively. Other endocannabinoids are noladin ether
and virodhamine [9–11]. The cannabinoid receptors,
endocannabinoids as well as the enzymes responsible for their
synthesis or degradation, collectively constitute the
‘endocannabinoid system’ [12].
Cannabis sativa has a wide-world reputation as a psycho-
tropic drug [1]. Cannabis is usually smoked, but may also be
eaten, mixed in cakes or cookies or drunk in a liquid infusion
[13]. Only recently, did Cannabis and cannabinoid-based medi-
cines come to attention as a remedy for different medical con-
ditions. The sublingual oromucosal spray Sativex, composed of
whole plant extract containing both D9-THC and cannabidiol
(CBD) [THC:CBD = 1:1] have recently been approved for the
treatment of pain and spasticity in multiple sclerosis [14].e CC BY-NC-ND license (http://
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formulations of a synthetic THC approved for the treatment of
nausea and vomiting that complicate chemotherapy and which
are refractory to conventional antiemetic therapy. These agents
are also being used to improve appetite to treat weight loss
associated with human immunodeﬁciency virus infection and
cancer [15]. Medicinal Cannabis is also being used for a
variety of medical conditions including chronic pain,
depression, arthritis, and neuropathy [16–18]. The
endocannabinoid system is a target for the treatment of
neurodegenerative disease e.g., tics in Tourette syndrome,
levodopa-induced dyskinesia in Parkinson s disease and some
forms of tremor and dystonia [19,20].
Cannabinoid receptors and their endogenous ligands (anan-
damide and 2-arachidonoyl glycerol) have been identiﬁed in the
gastrointestinal tract and are involved in mediation of several
gastrointestinal functions e.g., relaxation of the lower oesopha-
geal sphincter, gastric acid secretion, gastric emptying, gastro-
intestinal motility and ﬂuid secretion [21,22]. Evidence thus
suggests that cannabinoid-based medicines might be beneﬁcial
in a number of gastrointestinal disorders.
The aim of this review is to compile and discuss the available
data pertaining to the effect of Cannabis and/or cannabinoids on
gastric acid secretion and gastric mucosal integrity.
2. Cannabis and gastric acid secretion
There are no clinical studies on the effect of Cannabis on
gastric acid secretion. In their study, however, on 90 human
volunteers participating in a vaccine development programme,
Nalin et al. 1978 [23] found that smoking Cannabis for more
than 2 days a week was associated with low gastric acid
output. On the other hand, several preclinical studies
suggested inhibition of gastric acid secretion by Cannabis or
individual cannabinoids. Thus, in rats subjected to pylorus-
ligation for (2–4) h (Shay rat), the administration of an etha-
nolic extract of C. sativa raised the gastric pH. Rats treated with
0.1 and 0.3 g/kg of Cannabis extract for 4 h had their gastric pH
raised from 2 to 4 and 4.5. In the 4 h pylorus-ligated rat,
Cannabis 1 g/kg raised pH slightly more than 0.05 g/kg of the
histamine H-2 receptor blocker ranitidine. In rats subjected to
pylorus-ligation for 2 h, ranitidine was more effective than
Cannabis (pH values were 2.2, 3.5 and 4 for control, Cannabis
and ranitidine, respectively) [24].
The effect of long-term treatment with Cannabis extracts rich
in D9-THC on gastric acid secretion was studied in the pylorus-
ligated rat model (Shay rat). Rats were treated with 5, 10 and
20 mg/kg of Cannabis extract (expressed as D9-THC) subcuta-
neously for 4 weeks and then subjected to pylorus-ligation (for
4 h) with or without gastric acid stimulation (using pentagastrin,
histamine or carbachol). The administration of low doses of
Cannabis i.e. 5 or 10 mg/kg D9-THC stimulated basal gastric
acid output and gastric volume. The high dose of 20 mg/kg,
however, had no effect on basal gastric acid secretion. The effect
of Cannabis on stimulated gastric acid secretion was somehow
different in that it inhibited gastric acid secretory responses
stimulated by pentagastrin or carbachol in a dose-dependent
manner. On the other hand, Cannabis pretreatment had no sig-
niﬁcant effect on acid output stimulated by histamine [25].
Cannabis's most active constituent D9-THC is CB1 receptor
agonist [6,7]. When administered intravenously (i.v.), synthetic
CB1 receptor agonists inhibited gastric acid secretion in theanaesthetized rat preparation. Thus, WIN55, 212-2, which is a
non-selective cannabinoid agonist decreased gastric acid secre-
tion stimulated by pentagastrin (10 mg/kg, i.v.) in anaesthetized
rats. The inhibitory effect of WIN55, 212-2 on gastric acid
secretion is likely to be mediated via CB1 receptors, since se-
lective CB1 receptor antagonists SR 141716A and LY320135t
antagonized its action. WIN55, 212-2, however, failed to affect
basal gastric acid secretion [26].
Similar data were provided by Adami et al. [27] who reported
inhibition of pentagastrin stimulated gastric acid secretion in
anaesthetized rats with lumen-perfused stomach by the non-
selective cannabinoid agonists WIN55, 212-2 and HU-210.
Gastric acid secretion stimulated by 2-deoxy-D-glucose (a cen-
trally acting secretagogue which stimulates gastric acid by
increasing efferent vagus activity) is inhibited by the cannabi-
noid agonists, thereby suggesting a centrally mediated inhibition
of gastric acid secretion by these synthetic cannabinoid agonists.
But in contrast to their effect on gastric acid stimulation by
pentagastrin or 2-deoxy-D-glucose, the two cannabinoid agonists
did not affect acid secretion stimulated by histamine. The study
pointed again to a role for CB1 receptors in inhibition of gastric
acid secretion by the synthetic cannabinoids since their effect
was blocked by a CB1 but not CB2 receptor antagonist. More-
over, vagal involvement is suggested by ﬁnding that the inhib-
itory effect of HU-210 on pentagastrin-induced acid secretion
decreased following bilateral cervical vagotomy and ganglionic
blockade with hexamethonium.
Using rat isolated parietal cells, Rivas and Garcuˆa [28],
however, reported inhibition of gastric acid secretion
stimulated by histamine after high concentration of D9-THC
(20 mM). Basal gastric acid secretion was unaffected.
Experiments in the isolated mouse stomach indicated the
ability of CB1 antagonism to increase gastric acid secretion.
Stimulation with ouabain (an inhibitor of Na+/K+-ATPase)
increased gastric acid secretion (by releasing acetylcholine from
cholinergic nerves). The addition of the CB1 receptor antagonist
SR 141716A further increased the ouabain-stimulated acid
secretion. In contrast, the cannabinoid agonist WIN55, 212-2
was without effect [29]. These data suggest a role for CB1
receptors in inhibiting gastric acid secretion.
The above in vivo and in vitro studies thus suggest that are
CB1 receptor stimulation with synthetic cannabinoids or C.
sativa extracts rich in D9-THC inhibits gastric acid secretion.
Given the data suggesting that the CB1 agonist THC reduces
transient lower oesophageal sphincter relaxations and gastro-
oesophageal reﬂux [30], cannabinoid-based medicines might
ﬁnd utility in the treatment of peptic ulcer disease including
reﬂux oesophagitis. Interestingly, a study on the symptoms of
withdrawal in human marijuana smokers reported ‘Stomach
pain’ on the fourth day of abstinence among the abstinence
symptoms [31]. One might thus speculate that the stomach pain
was due to a rebound increase in gastric acid secretion and/or
increased mucosal sensitivity.
3. The site of action of Cannabis
The secretion of gastric acid is controlled at different neural,
hormonal and paracrine levels. The parietal cells in the gastric
glands are the cells secreting and releasing hydrochloric acid.
The parietal cell bears receptors for acetylcholine, histamine, and
gastrin, the major stimuli for gastric acid secretion. Cholinergic
stimulation is carried out by acetylcholine released from
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muscarinic M3 receptors. Acetylcholine also stimulates acid
secretion indirectly by activating muscarinic M2 and M4 re-
ceptors on somatostatin D cells coupled to inhibition of so-
matostatin secretion. Histamine which is released from
enterochromafﬁn-like cells, binds to and activates histamine
H2 receptors located on parietal cells, is a powerful stimulus for
gastric acid secretion as well as gastrin released from G cells of
the pyloric antrum. Gastrin reaches parietal cells via the circu-
lation and stimulates the parietal cell directly and also indirectly
by releasing histamine from enterochromafﬁn-like cells. Gastrin
release from antral gastrin cells is stimulated by gastrin releasing
peptide and inhibited by somatostatin [32,33].
The precise site of action for Cannabis and/or cannabinoids
in mediating inhibition of gastric acid secretion is yet to be
elucidated. The presence of CB1 cannabinoid receptor
messenger RNA within the rat stomach was demonstrated in
full-wall thickness preparations of rat oesophagus and stomach
[34]. In the rat, CB1 receptors are present in pre- and post-
ganglionic cholinergic neural elements innervating smooth
muscle, mucosal, and submucosal blood vessels [27].
Accordingly, it has been suggested that the gastric
antisecretory effects of cannabinoids are mediated by
suppressing the vagal drive through activation of CB1 receptor
located on the vagal efferent pathways to the gastric mucosa
and not on parietal cells [35].
With the use of different techniques (immunohistochemical
staining, Western blot, polymerase chain reaction), the presence
of CB1 receptor has been shown on the acid-secreting parietal
cells within the gastric glands in biopsy samples from the gastric
mucosa of patients with dyspeptic symptoms [36]. This suggested
a role for CB1 receptors in control of gastric acid production.
Cannabis therefore might inhibit gastric acid secretion by a
direct action on the CB1 receptors located on parietal cells.
Cannabinoid CB1 receptors are also abundant in the central
nervous system [20]. Following absorption THC as well as other
cannabinoids are distributed to all tissues and accumulate in fatty
tissues and are slowly released thereafter [1]. Because of their
lipophilic properties, cannabinoids can easily cross the blood-
brain barrier and act on brain cannabinoid receptors [7,37].
There is also an evidence that the antiemetic action of THC
(0.05–1.00 mg/kg i.p.) is due to an effect at CB1 receptors in
speciﬁc regions of the dorsal vagal complex [38]. It is thus
possible that the gastric antisecretory effect of Cannabis or
cannabinoids is due to a central rather than a peripheral site of
action i.e. by decreasing central efferent vagus activity.
In their study, Adami et al. [39], however, have shown that
the central (intracerebroventricular: i.c.v.) administration of the
synthetic cannabinoid agonists, WIN55, 212-2 or HU-210,
failed to inhibit basal gastric acid secretion or that stimulated
by pentagastrin in anaesthetized rats with lumen-perfused
stomach. This suggested that a peripheral rather than a central
CB1 receptor mechanism is likely to be involved in the inhibi-
tory effect of cannabinoids on gastric acid section [39].
4. Cannabis and gastric mucosal damage
Several preclinical studies provided data that supports a
protective effect for Cannabis or cannabinoids in the stomach. In
rats, D9-THC (100 mg/kg) given via subcutaneous or oral routes
inhibited the development of gastric ulcers induced by pyloric-
ligation (Shay rat) with the protective effect of D9-THC beingmost evident following subcutaneous compared with the oral
route of administration. D9-THC decreased gastric juice volume
but not free and total acidity [40].
In their experiments, De Souza et al. [41] demonstrated that
treatment with a C. sativa extract was able to protect the rat
stomach against restraint induced ulcers. Rats were treated
with different doses of the extract (5.0, 10.0, 20.0, 40.0 and
60.0 mg/kg, i.p.) both 24 h and immediately before
immobilization. Alternatively, the extract (40 and 60 mg/kg)
was given for 20 d prior to immobilization. The percentage of
rats with lesions decreased with acute treatment reaching
41.7% for the dose of 60 mg/kg vs. control value of 65.6%–
82.7%. This contrasted with chronic administration where the
percentage of rats displaying lesions was 94.7% vs. control
value of 100%, indicating that no protection occurred. These
results also demonstrated that chronic Cannabis injection for
20 d resulted in the development of tolerance to the
mechanisms of the anti-stress ulcer effect of Cannabis. Inter-
estingly, in unrestrained animals, treatment with Cannabis
extract at 40 or 60 mg/kg was associated with the development
of gastric ulceration. Thus, only in the presence of stress, did
Cannabis prevented gastric lesions, but the effect is evident in
the acute and not in the long-term treatment.
Other researchers have shown that 2 h pretreatment with D9-
THC (10 mg/kg, i.p.) prevented the gastric mucosal haemor-
rhagic streaks evoked by administration of the non-steroidal
anti-inﬂammatory drug (NSAID) diclofenac in mice; the effect
being attenuated by the CB1 receptor antagonist rimonabant [42].
Subsequent experiments in mice showed that D9-THC given via
oral or intraperitoneal routes prior to diclofenac, decreased the
development of gastric hemorrhagic streaks. D9-THC given
i.p. was more potent in reducing diclofenac-induced gastric ul-
cerations compared to the oral route. Thus while i.p. D9-THC
decreased diclofenac-induced gastric hemorrhages at a dose of
0.1 mg/kg and higher, the effect of orally given D9-THC was
evident at a dose of 2.5 mg/kg and above. However, at a dose of
10 or 50 mg/kg D9-THC given via i.p. or oral route inhibited the
development of lesions to almost the same extent. Moreover,
there was no difference between 10 or 50 mg/kg D9-THC given
via i.p. or oral route in the degree of their ulcer preventive effect
[43]. Using a simple ethanolic Cannabis extract, Wallace et al.
[44] found that oral (but not systemic) administration resulted
in a decrease in the severity of gastric damage caused by the
NSAID naproxen. The extract was administered either orally
at doses of 1, 3 and 10 mg/kg or i.p at a dose of 30 mg/kg
30 min prior to oral administration of naproxen and rats
euthanized 3 h later. The authors found that oral pretreatment
with Cannabis inhibited the development of gastric lesions.
Complete protection occurred with the 10 mg/kg of cannabis
extract, while at 3 mg/kg there was 80% inhibition of the
lesions. In contrast, Cannabis at 10 mg/kg given via i.p. route
was without effect. The gastroprotective effect of the extract
(10 mg/kg, orally) was blocked by a CB1 antagonist (but not a
CB2 antagonist) and thus CB1-mediated [44]. The discrepancy
between the oral and i.p. routes is not expected since orally
administered THC has a reduced systemic bioavailability
owing to gastric degradation with the presence of acids and
extensive ﬁrst-pass metabolism in the liver [1,45].
Studies have also assessed the effect of long-term treatment
with Cannabis extract on the chemically-induced gastric dam-
age. Rats received daily subcutaneous injections of D9-THC rich
Cannabis extract for 4 weeks prior to pylorus-ligation and oral
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(96%). In these experiments, Cannabis given at 5, 10 and
20 mg/kg of Cannabis extract (expressed as D9-THC) inhibited
the development of gastric mucosal damage in a dose-dependent
manner [25]. These data does not support that tolerance to the
gastroprotective action of Cannabis develops after repeated
administration.
Gastric mucosal protective effects have also been reported for
synthetic cannabinoids as well as endocannabinoids. In their
study, Germano et al. [46] provided data that the non-selective
cannabinoid receptor agonist WIN55, 212-2 decreased stress-
induced gastric ulcers in rats. The cannabinoid CB1 receptor
antagonist SR 141716A itself had no effect on stress-induced
lesions. SR 141716A (but not by the cannabinoid CB2 receptor
antagonist SR 144528), however, reversed the protective effect
of WIN55, 212-2, thus suggesting the involvement of CB1
receptors.
A study by Dembiñski et al. [47] found that anandamide (a
natural endogenous ligand for CB1 receptor) given i.p. prior
to water immersion and restrain stress decreased the
development of gastric mucosal lesions. The synthetic CB1
receptor antagonist AM 251 antagonized this effect of
anandamide, suggesting that CB1 receptors are involved. In
the study of Rutkowska and Fereniec-Gołebiewska [48]
ACEA (arachidonyl-2-chloroethylamide), the selective canna-
binoid CB1, was given (i.p.) 1 h prior to oral administration of
acetylsalicylic acid and rats euthanized 3 h later. In this study,
ACEA inhibited the development of gastric mucosal lesions
due to the NSAID with almost total protection being observed
after 5 mg/kg of ACEA. Meanwhile, the reference drug ranit-
idine at 60 mg/kg reduced gastric lesions to 5.6% of control
value.
Shujaa et al. [49] provided data that activation of central
cannabinoid receptors resulted in gastric mucosal protection.
The authors found that anandamide (an endocannabinoid), its
biologically stable analogue methanandamide and the synthetic
agonist WIN55, 212-2 reduced the ethanol-induced gastric
mucosal lesions. The protective effect was evident after either
peripheral (intravenous) or central (i.c.v.) administration. Cen-
trally administered CB1 receptor antagonist reversed the effect of
centrally administered anandamide and methanandamide while
naloxone (a non-selective opioid receptor antagonist) reversed
the effect of intravenously administered anandamide, meth-
anandamide and WIN55, 212-2. Thus, central cannabinoid CB1
and opioid receptors were involved in the gastric protection by
cannabinoids.
Moreover, increasing the levels of endogenous cannabinoids
resulted in gastric protection. Fatty acid amide hydrolase is an
enzyme which catalyses the intracellular hydrolysis of the
endocannabinoid anandamide and other bioactive lipid amides
[50]. Using URB937, an inhibitor of FAAH, Sasso et al. [51]
observed a reduction in both the number and severity of
gastric lesions produced by indomethacin in mice. 2-
arachidonylglycerol is degraded mainly by monoacylglycerol
lipase, but also by fatty acid amide hydrolase [6,7,52].
Kinsey et al. [42] administered diclofenac (100 mg/kg, p.o.) to
mice so as to induce gastric mucosal lesions. The authors found
that pretreatment with JZL184 (an inhibitor of 2-arachidonoyl
glycerol inactivation by monoacylglycerol lipase) attenuated
diclofenac-induced gastric hemorrhagic streaks. Meanwhile, 2-
AG administered i.p. 2 h prior to diclofenac failed to prevent
the NSAID-induced gastric lesions. JZL184 signiﬁcantlyincreased 2-AG in the stomach. Pro-inﬂammatory cytokines (IL-
1b, IL-6, tumour necrosis factor-alpha) increased in the stomach
of diclofenac-treated mice and these were mitigated by JZL184.
Rimonabant, a CB1 receptor antagonist (but not the CB2 receptor
antagonist SR 144528) antagonized the effect of D9-THC,
thereby, suggesting a CB1 mechanism. Further experiments in
mice given diclofenac showed that repeated daily injection of
JZL184 for 6 d protected against gastric mucosal damage caused
by the NSAID. In contrast to the effect of the high dose of the
agent (16 mg/kg), there was no tolerance associated with the
low dose (8 mg/kg) [53]. The above data collectively indicated
that stimulation of the endocannabinoid system mediates gastric
mucosal protection.
5. Mechanism (s) of gastric protection by Cannabis
The integrity of the gastric mucosa is maintained due to a
balance between ‘mucosal aggressive factors’ and the so called
‘gastric mucosal protective mechanisms’ [54]. The gastric
mucosa is constantly exposed to high concentrations of
luminal acid. Other aggressive factors in the lumen are
pepsins, bile reﬂuxed from incompetent pyloric sphincter,
bacteria, ethanol and drugs especially the non-steroidal anti-in-
ﬂammatory drugs (NSAIDs) capable of inhibiting the synthesis
of cytoprotective prostaglandins. The mucosa's ability to with-
stand acid and other injurious agents is due to several mecha-
nisms collectively is known as the gastric mucosal barrier. The
mucus-bicarbonate layer together with surface-active phospho-
lipids barrier constitute the ﬁrst line of defence or the pre-
epithelial barrier. The surface epithelial cells capable of rapid
turnover and migration (restitution) and releasing mucins, bi-
carbonate, phospholipids, prostaglandins, trefoil peptides form
the second line of defence. Other important defence mechanisms
of gastric mucosa are cytoprotective prostaglandins, mucosal
sulfhydryl content, adequate mucosal blood ﬂow, and sensory
afferent innervations. The development of gastric mucosa
damage implies a breach in the balance between aggressive and
defencive factors [55–58].
It is thus obvious that the management of peptic ulcer disease
involves removal or neutralizing aggressive factors especially
gastric acid e.g., via antacids or acid inhibitors acting on hista-
mine H2 receptors or the proton pump. Strengthening natural
defences is another approach e.g., with the use of drugs such as
sucralfate or cytoprotective prostaglandins [59]. Protecting the
gastric mucosa independently of gastric acid inhibition is
termed cytoprotection. This term was originally introduced by
Robert et al. [60] referring to the unique ability of
prostaglandins to protect the gastric mucosa from noxious
agents such as 0.6 N HCl, 0.2 M NaOH, 25% NaCl or 96%
ethanol, independently of gastric acid inhibition. Gastric
cytoprotection was also proved for small doses of
antisecretory agents, retinoids and growth factors [61]. Clearly,
since Cannabis and cannabinoid agonists have been shown to
inhibit gastric acid secretion, the protective effect of Cannabis
cannot be ascribed to a cytoprotective property.
Another mechanism by which the stomach resists the
chemical-induced injury is adaptive cytoprotection. Here,
exposure of the gastric mucosa to luminal diluted ulcerogens or
mild irritants will result in less damage following later exposure
to strong necrotizing agents [62]. Several mechanisms have been
postulated to account for adaptive cytoprotection including
endogenous prostaglandin synthesis, stimulation of mucus or
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calcitonin gene-related peptide from the sensory nerves [64].
Cannabis or cannabinoid agonists, administered via systemic
routes, however, were able to exert protective effect
[25,41,43,44,46] making adaptive cytoprotection an unlikely
mechanism. It remains to be established whether Cannabis
administered into the gastric lumen acts as a mild irritant and
thereby protecting the stomach via adaptive cytoprotection.
The effects of Cannabis are, however, the sum of its con-
stituents. There are more than 70 different cannabinoids and
these may have effects that are synergistic with or antagonistic to
D9-THC effects [65,66]. Other important constituents are
terpenoids and the ﬂavonoids ﬂavocannabiside [66]. One
terpenoid that is beta-caryophyllene has been shown to inhibit
the development of gastric lesions evoked by ethanol or 0.6 N
HCl when given orally to rats [67].
6. Cannabis strengthen gastric mucosal defences
Several mechanisms are likely to account for the ability of
Cannabis or individual cannabinoid agonists to protect the
stomach against noxious injury. Cannabis and/or individual
cannabinoids inhibit gastric acid secretion [24–27], thereby,
lessening the ability of this most powerful aggressive factor to
threaten the gastric mucosa. Studies also indicated that
Cannabis administration increases mucus secretion in the
gastric mucosa [25]. Mucus is secreted by the mucous neck
and surface epithelial cells and plays an important role in
protecting the surface epithelial cells from luminal acid and
other injurious agents. Mucus retards diffusion of luminal acid
into the mucosa and together with bicarbonate secreted by the
epithelium forms a pH gradient with near-neutral pH at the
surface of the mucosa [68,69].
Luminal pepsins constitute an important aggressive factor
capable of digesting mucus and thereby increasing the suscep-
tibility of gastric mucosa to other injurious factors [70]. Studies in
pylorus-ligated rats treated with Cannabis extract for 4 weeks
indicated that Cannabis did not affect basal pepsin secretion.
Cannabis, however, decreased pepsin secretion when the
stomach is stimulated with pentagastrin and carbachol. Cannabis
also decreased pepsin secretion following ethanol administration
in rats [25].
Reactive oxygen intermediates have been implicated in the
development of gastric mucosal injury due to ischaemia/reper-
fusion, ethanol, NSAIDs, and bacteria [71]. Cannabis has been
shown to decrease lipid peroxidation and to increase reduced
glutathione content and catalase activity in gastric mucosa [25].
Cannabis also inhibited mucosal nitric oxide [25]. Although a
vasodilator effect of physiological concentrations of nitric
oxide help the mucosa to withstand noxious challenge, high
concentrations are likely to have a damaging effect [72–74].
Cannabis thus might protect the gastric mucosa by virtue of
an antioxidant action.
Mucosal inﬂammation plays an important role in the devel-
opment of gastric ulcers and although initial inﬂammatory
response to the gastric mucosa helps to minimize or limit tissue
damage, an exaggerated or uncontrolled response is detrimental
to the mucosal integrity [69,75]. Cannabis has been shown to
inhibit the pro-inﬂammatory cytokine tumour necrosis factor-
alpha in mucosal homogenates [25], an action which might
help to minimize the extent of mucosal damage.Cannabis thus exerts antioxidant and anti-inﬂammatory ef-
fects in the gastric mucosa. It is to be noted, however, that these
actions of Cannabis were evident only when the gastric mucosa
was challenged with increased acid secretion or after exposing
the mucosa to noxious agents such as acidiﬁed aspirin and
ethanol and were not apparent under basal conditions [25].
One important factor in determining the ability of the gastric
mucosa to resist gastric acid and other noxious agents is gastric
mucosal blood ﬂow [57]. This has been inferred from studies
showing that interference with the blood supply to the mucosa
i.e. ischaemia resulted in the development of gastric mucosal
damage or aggravated the extent of mucosal damage evoked by
NSAIDs [76,77] or ethanol [78]. On the other hand, agents which
increase gastric mucosal blood ﬂow such as isoproterenol [79],
vasodilator prostaglandins [80] or capsaicin-type agents [81–83]
helped to protect against noxious challenge. In this context,
data have been provided that the endocannabinoid anandamide
increases gastric mucosal blood ﬂow [47]. There is also an
evidence for a vaso-relaxant action for methanandamide in rat
gastric arteries. This effect was independent of cannabinoid re-
ceptors [84]. It is thus possible that a vasodilatory action is
involved in the gastric protective effects of Cannabis and or
cannabinoids.
7. Conclusions
Cannabis and/or individual cannabinoids inhibit gastric acid
secretion. The inhibitory effect of Cannabis/cannabinoid agonists
on gastric acid secretion is likely to be mediated via CB1 re-
ceptors. The inhibitory effect might be mediated through activa-
tion of CB1 receptor located on the vagal efferent pathways.
There is also an evidence for a possible direct effect for Cannabis
on the CB1 receptors located on parietal cells. Cannabis could
also inhibit secretion by decreasing central efferent vagus activity.
There appears to be no densistization to the action of cannabis
following long-term administration of the herb. Cannabis inhibits
the development of gastric ulcers induced by pyloric-ligation
(Shay rat), restraint induced ulcers, and NSAIDs. Exogenous
administration of endocannabinoids or increasing the levels of
endogenous cannabinoids resulted in a gastric protection. The
gastroprotective effect of cannabis could be blocked by a CB1
antagonist. Activation of central cannabinoid receptors results in
gastric mucosal protection. Cannabis thus exerts antioxidant and
anti-inﬂammatory effects in the gastric mucosa. It is possible that
a vasodilatory action is involved in the gastric protective effects
of cannabis and or cannabinoids. Cannabinoids-based medicines
might ﬁnd utility in treatment of peptic ulcer disease including
gastroesophageal reﬂux.
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